Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 445 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Unfractionated Heparin Clear all
Completed Early Phase 1 Interventional

Recurrent Urinary Tract Infections and Heparin (RUTIH Trial)

NCT02246270
View directory record Official record
Conditions
Recurrent Urinary Tract Infections
Interventions
Intravesical Heparin, Placebo
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 18, 2026, 1:14 AM EDT
Terminated Phase 2 Interventional Results available

Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer

NCT00633061
View directory record Official record
Conditions
Childhood Cancer, Central Venous Catheters, Deep Vein Thrombosis, Catheter-related Infection, Catheter-related Occlusion
Interventions
Enoxaparin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

NCT01419977
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Placebo, Dalteparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)

NCT00854139
View directory record Official record
Conditions
Multiple Myeloma, End Stage Renal Disease
Interventions
Cyclophosphamide, anti-thymocyte globulin, Kidney transplant, Thymic irradiation, Bone marrow transplant from a related donor
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Early Phase 1 Interventional Results available

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin

NCT02970032
View directory record Official record
Conditions
Deep-Venous Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions
Real time heparin dose adjustment, Standard heparin dose
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 18, 2026, 1:14 AM EDT
Terminated Not applicable Interventional

Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD

NCT03255057
View directory record Official record
Conditions
Acute Exacerbation of COPD
Interventions
Hemolung Respiratory Assist System, Invasive mechanical ventilation
Device
Lead sponsor
Alung Technologies
Industry
Eligibility
40 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
32
States / cities
Sacramento, California • Denver, Colorado • Newark, Delaware + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Not applicable Interventional Results available

GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)

NCT00541307
View directory record Official record
Conditions
Peripheral Vascular Diseases
Interventions
Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Oceanside, California • Chicago, Illinois • Columbia, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB

NCT00079508
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Oct 18, 2026, 1:14 AM EDT
Active, not recruiting No phase listed Observational

Assessing Chest Pain Using Point-of-Care High-Sensitivity Troponin I in the Emergency Department

NCT06899776
View directory record Official record
Conditions
ACS (Acute Coronary Syndrome)
Interventions
Abbott i-STAT point of care (POC) device
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Charlotte, North Carolina • High Point, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 1:14 AM EDT
Not listed Phase 4 Interventional

Comparing Bivalirudin Versus Heparin/ GP IIB/IIA in Patients Undergoing PCI

NCT00476944
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
Gold, Herman K., MD
Individual
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2007 · Synced Oct 18, 2026, 1:14 AM EDT
Terminated Phase 2 Interventional

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

NCT00981903
View directory record Official record
Conditions
Venous Thromboembolism, Cancer
Interventions
Tinzaparin sodium
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

NCT00679588
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin Sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 18, 2026, 1:14 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Off-pump Versus On-pump Coronary Artery Bypass Grafting in Frail Patients

NCT02338947
View directory record Official record
Conditions
Frail Elderly, Coronary Artery Disease
Interventions
Off-pump coronary-artery bypass grafting, On-pump coronary-artery bypass grafting
Other
Lead sponsor
University of Sao Paulo General Hospital
Other
Eligibility
60 Years and older
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Not applicable Interventional Results available

Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

NCT01999179
View directory record Official record
Conditions
Venous Thrombosis, Neoplasms
Interventions
Heparin, Low-Molecular-Weight, or direct oral anticoagulants
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Columbus, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 18, 2026, 1:14 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)

NCT04861103
View directory record Official record
Conditions
Pregnancy, High Risk, Anticoagulants
Interventions
Lovenox
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Not applicable Interventional Results available

Strategies for Anticoagulation During Venovenous ECMO

NCT04997265
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism
Interventions
Low intensity anticoagulation, Moderate Intensity Anticoagulation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 18, 2026, 1:14 AM EDT
Not listed Phase 4 Interventional

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

NCT02342444
View directory record Official record
Conditions
Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
Interventions
Enoxaparin Sodium Injection 30 mg BID, Enoxaparin Sodium Injection 40 mg QD
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 100 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 18, 2026, 1:14 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients

NCT00041782
View directory record Official record
Conditions
Neoplasms, Deep Vein Thrombosis
Interventions
Dalteparin (Fragmin)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 4 Interventional Results available

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

NCT04505774
View directory record Official record
Conditions
Covid19
Interventions
theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor
Drug
Lead sponsor
Matthew Neal MD
Other
Eligibility
18 Years and older
Enrollment
3,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
81
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 18, 2026, 1:14 AM EDT
Active, not recruiting Phase 4 Interventional

Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study

NCT04496362
View directory record Official record
Conditions
ECMO, Heparin, Respiratory Failure
Interventions
subcutaneous heparin anticoagulation
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 2 Interventional

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

NCT00306254
View directory record Official record
Conditions
Venous Thrombosis
Interventions
PD 0348292, Enoxaparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2007 · Synced Oct 18, 2026, 1:14 AM EDT
Terminated Not applicable Interventional Results available

Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies

NCT04764396
View directory record Official record
Conditions
Pancreas, Mass Lesion
Interventions
Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe), Saline
Combination Product · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 18, 2026, 1:14 AM EDT
Recruiting Phase 2Phase 3 Interventional

Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies

NCT04924322
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 17 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 18, 2026, 1:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

INR Comparison Testing in Cardiac Surgery

NCT03267823
View directory record Official record
Conditions
Coagulation Disorder
Interventions
International Normal Ratio (INR)
Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 18, 2026, 1:14 AM EDT